Quick Dispatch:
Your eli lilly phase 3 trial retatrutide A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your eli lilly phase 3 trial retatrutide A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) ships.
Need Help?
Questions about eli lilly phase 3 trial retatrutide A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for eli lilly phase 3 trial retatrutide A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) in your area.
retatrutide (LY3437943) / Eli Lilly
26.67
Eli Lilly's tirzepatide showed positive results in late-stage trial as treatment for heart failure
22.95
Eli Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal phase 3 obesity trial
20.00
Eli Lilly and Company Reports Phase 3 TRIUMPH-1 Trial Shows Up to 30.3% Weight Loss with Retatrutide in Obesity
24.12
Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:
25.49
ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial
29.60
Eli Lilly just made history and if you're looking to start your weight loss journey, retatrutide changes everything. ➡️ On May 21, 2026, the results of TRIUMPH-1 were announced — a pivotal
23.33
